Cargando…
PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
Peroxisome proliferator-activated receptor-γ (PPAR-γ) has emerged as one of the most extensively studied transcription factors since its discovery in 1990, highlighting its importance in the etiology and treatment of numerous diseases involving various types of cancer, type 2 diabetes mellitus, auto...
Autores principales: | Ballav, Sangeeta, Biswas, Bini, Sahu, Vishal Kumar, Ranjan, Amit, Basu, Soumya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601205/ https://www.ncbi.nlm.nih.gov/pubmed/36291082 http://dx.doi.org/10.3390/cells11203215 |
Ejemplares similares
-
PPARγ and PPARδ as Modulators of Neoplasia and Cell Fate
por: Glazer, Robert I., et al.
Publicado: (2008) -
Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
por: Ayza, Muluken Altaye, et al.
Publicado: (2020) -
Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015) -
Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γ Agonist against MPTP
por: Swanson, Christine R., et al.
Publicado: (2013) -
Structural and Dynamic Elucidation of a Non-acid PPARγ Partial Agonist: SR1988
por: Frkic, Rebecca L., et al.
Publicado: (2018)